Clinical Trial Update: Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports termination of a Phase 1/2 study evaluating Taxotere (docetaxel) with prednisone plus sunitinib in chemotherapy-naïve, hormone-refract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Prostate Cancer

Drugs mentioned

• PREDNISONE (Prednisone)
• Sutent (sunitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: John P. Fruehauf | Conditions: Prostate Cancer, Adenocarcinoma of the Prostate | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2013-06-06